Key facts
- BeOne Medicines Ltd. filed SCHEDULE 13D/A for Leap Therapeutics, Inc. Common Stock, par value $0.001 per share (LPTX).
- Disclosed ownership: 0%.
- Date of event: 31 Oct 2024.
BeOne Medicines Ltd. - 31 Oct 2024 SCHEDULE 13D/A Report for Leap Therapeutics, Inc. Common Stock, par value $0.001 per share (LPTX)
- Filing manager
- BeOne Medicines Ltd.
- Reporting owner
- BeiGene, Ltd.
- Symbol
- LPTX
- Disclosed shares
- 1,215,306 shares
- Ownership percentage
- 0%
- Form type
- SCHEDULE 13D/A
- Filing time
- 31 Oct 2024, 17:40:59 UTC
- Event date
- 31 Oct 2024
- SEC filing
- View on sec.gov
Reporting parties
Subject security
Ownership signal
SEC evidence
Key filing fact
BeOne Medicines Ltd. disclosed 0% ownership in Leap Therapeutics, Inc. Common Stock, par value $0.001 per share (LPTX) on 31 Oct 2024.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 31 Oct 2024, 17:40.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (1)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BeiGene, Ltd. | 0% | 1,215,306 | 1,215,306 | 0 | BeiGene, Ltd. | Chan Lee Senior Vice President, General Counsel | 0001651308 |
CIK / CUSIP context first